title: Retigabine.
abstract: Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.
authors.affiliation: Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, USA. rjportermd@aol.com
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Porter
authors.forename: Virinder
authors.initials: V
authors.lastname: Nohria
authors.forename: Chris
authors.initials: C
authors.lastname: Rundfeldt
mesh_terms: D000818:Animals; D000927:Anticonvulsants; D001921:Brain / Q000187:drug effects; D002219:Carbamates; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D010655:Phenylenediamines
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine